REG - Avacta Group PLC - Posting of Annual Report and Revised Notice of AGM

AvactaAnnouncement

09/06/2025 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250609:nRSI0774Ma&default-theme=true

RNS Number : 0774M  Avacta Group PLC  09 June 2025

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Posting of Annual Report and Revised Notice of AGM

 

LONDON and PHILADELPHIA - June 9, 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing innovative, targeted oncology drugs, today
announces

that its Annual Report and Accounts for the year ended December 31, 2024 and
the Notice of Annual General Meeting ("AGM") are available on the Company's
website at https://avacta.com/investors/investor-resources/
(https://avacta.com/investors/investor-resources/) .

 

Copies of the Annual Report and Accounts and the Notice of AGM will be posted
today to registered shareholders who have elected to receive them in paper
form.

 

The Company had intended to hold the AGM on Monday, June 30, 2025 however due
to some logistical considerations and investor feedback on the prior date, the
Company will now convene the AGM for Wednesday, July 2, 2025 at 9:00 am BST.
The meeting will be held at the offices of Peel Hunt LLP, 7(th) Floor, 100
Liverpool Street, London EC2M 2AT (the "Venue").

 

The Venue has a capacity of approximately 120 people. Registered shareholders
have a right to attend the AGM.  In addition, the current expectation is that
the chair of the AGM will, at their discretion, permit beneficial shareholders
to attend in person. Shareholders (registered or beneficial) who propose to
attend the AGM in person are requested to pre-register their interest and, to
assist the Company in its preparation for the AGM, prove their shareholding by
emailing their letter of representation to ICR at avacta@icrhealthcare.com
(mailto:avacta@icrhealthcare.com)  by Friday, June 27, 2025. Any failure to
pre-register will not, of itself, preclude a registered shareholder from
attending the AGM in person (or by proxy).

 

Only registered shareholders who attend in person or by proxy will be able to
vote on the day. Details of how to submit a proxy vote are contained in the
Notice of the AGM.

 

The Company will provide a business update following the AGM, which will be
recorded and uploaded on the Company's website for shareholders who are not
able to attend in person.  All presentation materials will be made available
on the website at the end of the day and no new material information will be
provided.

 

Early pre-registration to attend the AGM in person is recommended as the
venue's capacity is limited (as referred to above) and, for non-registered
shareholders, registrations will be dealt with on a first come, first served
basis.  Those attending in person are also recommended to arrive around 30
minutes before the start of the meeting to ensure that the venue's admission
procedures can be adhered to.

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)

 James Steel / Chris Golden                                 www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)

 Emma Earl / Will Goode / Mark Rogers                       https://panmureliberum.com/ (https://panmureliberum.com/)

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

 

About Avacta - www.avacta.com (http://www.avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBLGDLUBGDGUC